US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.89
▼-1.02%
TSLA
$378.69
▲+2.18%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.89
▼-1.02%
TSLA
$378.69
▲+2.18%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
SNDK
$1,704.16
▼-0.92%
AAPL
$332.89
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Merus N.V. - Common Shares
(NQ:
MRUS
)
90.00
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merus N.V. - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
September 30, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
September 17, 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From
Merus N.V.
Via
GlobeNewswire
MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
↗
August 01, 2024
MRUS stock results show that Merus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
August 01, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
July 24, 2024
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback
From
Merus N.V.
Via
GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
July 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
July 01, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
June 03, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
June 02, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
May 29, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 29, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
May 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
May 28, 2024
Via
Benzinga
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Crude Oil Rises 1%; Verastem Shares Slide
↗
May 24, 2024
Via
Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
May 24, 2024
Via
Benzinga
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
↗
May 24, 2024
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with...
Via
Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
↗
May 24, 2024
Via
Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
↗
May 24, 2024
The company passed investors' bar for success in a study of a head-and-neck cancer treatment.
Via
Investor's Business Daily
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
↗
May 24, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
May 24, 2024
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!
Via
InvestorPlace
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024
From
Merus N.V.
Via
GlobeNewswire
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
May 13, 2024
From
Merus N.V.
Via
GlobeNewswire
MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
MRUS stock results show that Merus beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
May 06, 2024
If approved, Zeno will be the first targeted therapy for NRG1+ cancer
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
April 24, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
April 08, 2024
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
